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Objective: To identify expression proﬁles (EP) associated with aseptic loosening of total knee arthroplasty
(TKA) and to compare them with EP observed in total hip arthroplasty (THA), and primary knee and hip
osteoarthritis (OA).
Design: Gene EP of TNF, IL-6, IL-8, CHIT1, BMP4, CCL3, CCL18, MMP9, RANKL, OPG, DC-STAMP and SOCS3
were assessed using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on tissues
retrieved from patients with aseptically failed TKA (n ¼ 21), THA (n ¼ 41) and primary knee (n ¼ 20) and
hip (n ¼ 17) OA. Immunohistochemistry was applied to localize the proteins.
Results: When compared to knee OA, the pseudosynovial tissue in TKA exhibit (1) elevation of alternative
macrophage activation marker (CHIT1), chemokine (IL-8), and a proteolytic enzyme (MMP9); (2) down-
regulation of pro-inﬂammatory cytokine (TNF), osteoclastic regulator (OPG) and a stimulator of bone
formation (BMP4); (3) no difference in IL-6, CCL3, CCL18, RANKL, DC-STAMP and SOCS3. The EP in TKA
differed fromEP in aseptically failed THAby lower CCL3 andDC-STAMPmRNAandprotein expression. EP of
all studied inﬂammatory and osteoclastogenic molecules were similar in knee and hip OA.
Conclusions: Comparing to OA, aseptic loosening of TKA is associated with upregulated expression of
CHIT1, IL-8 and MMP9, dysregulated RANKL:OPG ratio and low levels of inﬂammatory cytokines. Similar
cytokine proﬁles were associated with primary knee and hip OA. Further research is required to explain
the differences in CCL3 and DC-STAMP expression between failed TKA and THA.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.ne morphogenetic protein 4;
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Aseptic loosening is the main long-term adverse event associ-
ated with total knee (TKA) and hip (THA) arthroplasties. Although
several theories on the cause of these complications have been
proposed1, there is growing evidence for particle disease contri-
bution to the late aseptic loosening2e4. Accordingly, this process is
induced and perpetuated by long-term stimulation of peri-
prosthetic tissues by particles deliberated from prosthetic surfaces.
When released from the bearing surfaces of the implant, wear
particles serve as inducers of an innate immune response in the
surrounding periprosthetic tissues. Receptors on immune cells are
stimulated by prosthetic by-products inducing expression of genes
regulating the inﬂammatory response on the danger/damage sig-
nals5,6. The key cell populations shaping above-mentionedtd. All rights reserved.
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body giant cells7e9. Upon activation, these cells release a spectrum
of pro-inﬂammatory cytokines, which in turn promote osteoclast
differentiation and subsequent bone resorption via deregulation of
RANKL-RANK-OPG axis10e12 and further recruitment of a number
of immune cells to the local site13.
Several studies have already been conducted to identify the
gene expression proﬁles (EP) of inﬂammatory and osteoclastogenic
molecules participating in periprosthetic osteolysis and aseptic
loosening, majority of them performed in vitro or in THA14e16. The
most comprehensive study on expression proﬁling in THA revealed
no increase in pro-inﬂammatory mediators such as TNF-a and IL-6,
and upregulation of CHIT1 and CCL18 suggesting the alternative
macrophage activation in end-stage osteolysis17. Similar compre-
hensive expression proﬁling study on tissues from aseptically
loosened TKA and its comparison to THA is still lacking.
Therefore, we investigated EP of a set of inﬂammatory and
osteoclastogenic molecules in pseudosynovial membrane obtained
from patients with aseptically loosened TKA. Candidate molecules
(TNF, IL-6, IL-8, CHIT1, BMP4, CCL18, CCL3, MMP9, RANKL, OPG, DC-
STAMP) were selected based on the osteolysis-associated proﬁle in
THA17. Additionally, we investigated the expression of SOCS3, an
inhibitor of IL-6 signalling, found induced by wear debris in cell
cultures of human osteoclast precursor cells18. The EP in TKA were
compared to those obtained in aseptically failed THA and knee and
hip osteoarthritis (OA). We believe that deeper understanding of
the mechanisms of osteolysis and aseptic loosening in total joint
replacements could contribute to a proposal of measures for their
prevention and treatment.
Methods
Subjects
Pseudosynovial tissues were obtained from 62 patients re-
operated for the aseptic failure (aseptic loosening, periprosthetic
osteolysis) of TKA (n¼ 21) and THA (n¼ 41). In primary OA, synovialTable I
Patient clinical characteristics
Knee joint
Failed TKA Primar
Patients, N 21 20
Gender (male/female) 5/16 7/13
BMI (kg/m2) 29.5 (22.9e38.9) 29.7 (2
Primary diagnosis
Primary OA 21 20
Postdysplastic arthritis 0 0
Ischaemic bone necrosis 0 0
Preoperative score
HHS e e
KSS pain 41.0 (32e48) 59.2 (2
KSS function 45.7 (30e60) 52.2 (3
Age at surgery 74.8 (56e88) 65.6 (5
Time from index to
revision surgery (yrs)
9.7 (2e15) e
Type of ﬁxation
Cemented 21 e
Partially cemented 0
Cementless 0
Bone defects F2A e 3y n.a.
F2B e 2
F3 e 2
T2A e 9
Wear rate (mm/year) n.a. e
n.a. not available, e not relevant, HHS e Harris Hip Score; KSS e Knee Society Score. All
* Only severe bone defects are shown (i.e., type 3 and higher at the acetabular site an
y AORI classiﬁcation20 e F1 and T1 bone defects are not shown.membrane was retrieved from 37 patients undergoing TKA (n ¼ 20)
and THA (n¼ 17). For detailed patient characteristics see Table I. Bone
defects were determined in terms of Saleh et al.19 and Anderson Or-
thopaedic Research Institute (AORI) classiﬁcation20. Infection cases
were excluded from all subjects of the study according to the diag-
nostic algorithm published previously21. Samples of pseudosynovial
tissues were collected also from a group of patients with TKA [C-TKA,
n ¼ 12; male/female 5/7; age mean (range): 68.8 yrs (60e83); time
from index surgery (range): 2.8 months (0.2e10.0)] and THA [C-THA,
n ¼ 14; 5/9; 64.1 (52e78); 10.0 (0.1e18.0)], who were revised due to
pain of unknownorigin, instability, or periprosthetic fracture,withno
clinical and radiographic signs of osteolysis and aseptic loosening at
the time of sampling.
The study included Czech Caucasian patients operated between
September2008andDecember2013at a single institutionbya single
surgeon (JG). Written informed consent about the usage of peri-
prosthetic tissues for the purpose of this study was obtained from
each subject and the local ethics committee approved the study.
Tissue sample processing and quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR)
Thin surface layer of a tissue covering an inner side of a joint
capsule was collected from patients re-operated due to aseptic
loosening immediately after the incision of the knee/hip joint
capsule. This sample is designated pseudosynovial membrane since
it resembles synovial membrane that had been removed from a
joint during index surgery. This tissue has been in permanent
contact with the prosthetic by-products (wear particles, metal ions
etc.), signals of danger/tissue damage all dispersed in a joint ﬂuid,
and it has been as well under repetitive pressure of joint ﬂuid until
the time of revision surgery, thus carrying relevant information on
the host response to prosthetic by-products22e24. Therefore,
pseudosynovial membrane has been used to investigate molecular
mechanisms contributing to aseptic loosening25e27. In primary
osteoarthritic groups, an inner side of synovial membrane was
sampled. Tissue specimens, approximately 2  5 mm in diameter,Hip joint
y OA Failed THA Primary OA
41 17
12/29 10/7
0.6e35.4) 29.6 (19.8e41.4) 29.2 (21.3e35.3)
18 17
18 0
5 0
59.6 (20e90) 48.8 (16e68)
0e69) e e
0e72) e e
2e79) 59.9 (31e86) 56.9 (28e68)
11.7 (3e18) e
3 e
5
33
Acetabular 15*
Femoral e 3
n.a.
0.17 (0.02e0.56) e
data are presented as mean values; minemax values are shown in parentheses.
d type 2 and higher at the femoral site according to Saleh classiﬁcation19).
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readily accessible area of the joint capsule. Representative exam-
ples of pseudosynovial membrane in failed TKA/THA and synovial
membrane in OA are shown in the On-line Supplement (Fig. E1). All
specimens were retrieved by a single surgeon (JG) and placed
immediately into the RNAlater (Ambion, Austin, USA).
After homogenisation (0.1 g tissues), total RNA was isolated
using mirVana miRNA kit (Ambion, Austin, USA) and transcribed
with Transcriptor First Strand cDNA Synthesis Kit with anchored dT
primers (Roche Applied Science, Indianapolis, USA) according to
the manufacturer's recommendation. The quantity and quality of
RNA samples were assessed by 2100 Bioanalyzer (Agilent Tech-
nologies, Palo Alto, USA) using RNA 6000 Nano assays. Quantitative
PCR was performed on RotorGene3000 as described elsewhere28; a
second-derivative method was used for calculations (RotorGene
Software 6.1.81, QIAGEN Inc., Valencia, CA), HPRT1 as a reference
gene17. For primer sequences and probes see Table E1 in the On-line
Supplement. Calibration curves for all genes revealed a PCR efﬁ-
ciency comprised in the range of acceptability (90e110%), an error
value < 0.2. The error value was calculated as the mean squared
error of the single data points ﬁtting to the regression line.
Immunohistochemistry
Bioptic tissue sampleswere taken identically as for RNA study and
independent samples from aseptically failed TKA (n¼ 7), THA (n¼ 7),
knee OA (n ¼ 5) and hip OA (n ¼ 5) were investigated. The bioptic
samples were processed and stained as described previously29. Pri-
mary antibodies were used as follows: RANKL (rabbit polyclonal
1:200,Abcam,Cambridge,UK),OPG (rabbit polyclonal 1:500,Abcam),
IL-8 (rabbit polyclonal 1:100,Novus Biologicals, Cambridge, UK), CCL3
(rabbit polyclonal 1:50, Abcam), DC-STAMP (rabbit polyclonal 1:200,
LifeSpan BioSciences, Seattle, WA, USA), SOCS3 (rabbit polyclonal
1:100, Abcam). In all cases, antigen retrievalwas performed in 10mM
citrate buffer, pH 6 (120C) using the high-pressure histoprocessor
HistosPro (Milestone, MI, USA); EnVision™ system (Dako, Glostrup,
Denmark) was used for antigen visualization as described previ-
ously29. The staining was evaluated semiquantitatively (amount of
positive cells multiplied by the staining intensity). The staining with
negative isotype control antibody (rabbit IgG, polyclonal e Isotype
Control, 1:100, Abcam) was performed for all examined tissues. The
staining for osteoclasts was performed using Anti-Tartrate Resistant
Acid Phosphatase (TRAP) antibody (ab49507, mouse monoclonal
1:75, Abcam). All primary antibodies used were tested on recom-
mended positive control tissue specimens.
Statistical analysis
Data analysis was performed using GraphPad Prism 5.01
(GraphPad Software, La Jolla, CA, USA) and SPSS 16.0 (SPSS Inc,
Chicago, IL, USA). Differences in mRNA levels between the cohorts
were assessed by non-parametric KruskaleWallis one-way anal-
ysis-of-variance-by-ranks test; non-parametric ManneWhitney
test was utilized to determine signiﬁcant differences between two
groups of patients. A P-value < 0.05 was considered as signiﬁcant.
Results
mRNA expression proﬁling in pseudosynovial membrane retrieved
from patients with aseptically failed TKAs and their comparison to
failed THAs and OA
To investigate the molecular mechanisms underlying aseptic
loosening and osteolysis in TKA/THA, the relative mRNA expression
levels of (1) alternative macrophage activation markers (CHIT1,CCL18), (2) pro-inﬂammatory cytokines (IL-6, TNF), (3) osteoclas-
togenic regulators (RANKL, OPG, DC-STAMP), (4) molecule involved
in bone development and bone formation (BMP4), (5) a proteolytic
enzyme (MMP9), (6) chemokines (IL-8, CCL3/MIP1a), and (7) an
inhibitor of IL-6 signalling (SOCS3) were determined in pseudosy-
novial tissues obtained from patients with aseptically failed TKA.
The mRNA EP in failed TKA were then compared to those in asep-
tically failed THA and patients with knee and hip OA.
Of studied molecules, signiﬁcant difference in TNF, IL-8, CHIT1,
BMP4, CCL3, MMP9, OPG, DC-STAMP and SOCS3 mRNA expression
was detected between the four cohorts (Fig. 1, Table II). Although
RANKL mRNA expression was altered amongst the study cohorts, a
signiﬁcant intergroup difference was not shown (P ¼ 0.075 by
KruskaleWallis test) [Fig. 1(J), Table II]. When compared to knee
OA, higher number of IL-8, CHIT1, and MMP9 mRNA transcripts
(P < 0.0001) [Fig. 1(C), (E), (F), Table II] and lower TNF and BMP4
mRNA expression [Fig.1(A), (D), Table II] was detected in failed TKA.
The expression of OPG tended to be lower in failed TKA comparing
to OA, however the difference did not reach signiﬁcance (P ¼ 0.06)
[Fig. 1(K), Table II]. Similarly, the difference in IL-6, CCL3, CCL18, DC-
STAMP, RANKL, and SOCS3 mRNA expression in TKA comparing to
osteoarthritic controls did not reach signiﬁcance [Fig. 1, Table II].
Next, we compared the EP obtained in TKA with aseptically
loosened THA. Analyses between TKA and THA groups revealed
lower CCL3 and DC-STAMP mRNA expression in TKA; however, the
difference in expression of TNF, IL-6, IL-8, CHIT1, BMP4, CCL18,
MMP9, RANKL, OPG, and SOCS3 between both groups did not reach
signiﬁcance (Fig. 1, Table II, On-line Supplement Fig. E2). We per-
formed also subanalysis on EP in THA patients with cemented and
uncemented arthroplasties and revealed similar EP in these patient
subgroups (data not shown).
We aimed also to investigate whether EP of studied inﬂamma-
tory and osteoclastogenic molecules differ between groups of pa-
tients with OA of knee and hip. The EP of all studiedmolecules (TNF,
IL-6, IL-8, CHIT1, BMP4, CCL18, CCL3, MMP9, RANKL, OPG, DC-
STAMP and SOCS3) did not differ between groups with knee and
hip OA (Fig. 1, Table II, On-line Supplement Fig. E2).
We performed also a comparison of RANKL/OPG ratio between
our study cohorts. Although the difference between four study
cohorts did not reach signiﬁcance, the RANKL/OPG ratio tended to
be higher in failed TKA comparing to THA patients and in knee
comparing to hip osteoarthritic controls (On-line Supplement
Fig. E3).
Comparison of CCL3, DC-STAMP and NF-kB mRNA expression
between cases and controls with stable implants
To further investigate the expression pattern of CCL3, DC-STAMP
and NF-kB in various stages of osteolysis in TKAs and THAs, the
relative mRNA expression levels were compared between tissues
from patients with aseptically failed TKAs and THAs and those from
patients with arthroplasty re-operated for other reason than
osteolysis and aseptic loosening, with no clinical and radiographic
signs of osteolysis and aseptic loosening at the time of sampling (C-
TKA, C-THA). Transcription factor NF-kB was chosen due to its
crucial role in regulation of CCL330 and other genes (including DC-
STAMP) involved in bone metabolism31 and biomaterial-induced
periprosthetic osteolysis30.
When comparing knee and hip joints, similar number of CCL3
transcripts was observed in C-TKA (mean relative expression 2.623,
95% conﬁdence interval (CI) 1.614e3.633) and C-THA (2.293,
1.408e3.178, P¼ 0.565) (Fig. 2). Expression of CCL3was higher in C-
TKA comparing to TKA (P ¼ 0.003), whereas in hip joint, higher
CCL3 expression was observed in THA comparing to C-THA
(P ¼ 0.018). Similar number of DC-STAMP transcripts was observed
Fig. 1. Distribution of relative mRNA expression (ratio target gene/reference HPRT1 gene) of (A) TNF, (B) IL-6, (C) IL-8, (D) BMP4, (E) CHIT1, (F) MMP9, (G) CCL18, (H) CCL3, (I) DC-
STAMP, (J) RANKL, (K) OPG, and (L) SOCS3 in pseudosynovial membrane tissues obtained from patients with aseptically failed TKA and THA and in synovial membrane obtained
from patients with primary knee (OA-knee) and hip (OA-hip) OA. Group means are indicated by horizontal bars, error bars indicate 95% CI; only P-values for signiﬁcant differences
between two groups of patients are stated.
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Table II
Comparison of gene EP between pseudosynovial tissues from aseptically failed TKA and THA and control osteoarthritic patients
TKA (N ¼ 21) THA (N ¼ 41) OA-knee (N ¼ 20) OA-hip (N ¼ 17) P (KruskaleWallis) P TKA
vs THA
P TKA vs
OA-knee
P THA vs
OA-hip
P OA-knee
vs OA-hip
TNF 0.30 (0.14e0.46) 0.41 (0.27e0.56) 0.64 (0.42e0.86) 0.56 (0.36e0.75) 0.006 0.167 0.002 0.076 0.573
IL-6 0.78 (0.27e1.29) 1.49 (0.50e2.49) 0.46 (0.26e0.66) 0.86 (0.19e1.52) 0.866 0.562 0.794 0.798 0.670
CHIT1 5.27 (3.18e7.35) 7.68 (4.87e10.48) 0.13 (0.05e0.22) 0.07 (0.02e0.13) <0.001 0.431 <0.001 <0.001 0.293
CCL18 1.34 (0.53e2.15) 1.92 (0.95e2.89) 1.18 (0.69e1.68) 2.16 (1.29e3.04) 0.185 0.677 0.457 0.088 0.085
IL-8 0.64 (0.29e1.00) 1.25 (0.53e1.97) 0.16 (0.09e0.23) 0.16 (0.09e0.23) <0.001 0.108 <0.001 <0.001 0.772
CCL3 1.10 (0.65e1.55) 4.08 (3.08e5.09) 1.20 (0.50e1.90) 1.19 (0.70e1.68) <0.001 <0.001 0.958 <0.001 0.512
MMP9 32.02 (20.40e43.65) 30.58 (24.31e36.85) 3.90 (0.90e6.90) 8.16 (1.94e14.37) <0.001 0.953 <0.001 <0.001 0.241
DC-STAMP 0.40 (0.10e0.70) 0.77 (0.43e1.12) 0.11 (0.07e0.15) 0.16 (0.06e0.25) <0.001 0.007 0.109 <0.001 0.964
OPG 1.24 (0.80e1.68) 1.31 (0.76e1.86) 2.31 (1.42e3.19) 2.94 (1.75e4.14) 0.005 0.613 0.059 0.005 0.455
RANKL 0.39 (0.22e0.56) 0.31 (0.24e0.38) 0.59 (0.35e0.83) 0.48 (0.32e0.63) 0.075 0.618 0.130 0.042 0.692
BMP4 0.57 (0.35e0.79) 0.55 (0.39e0.71) 1.15 (0.93e1.36) 1.35 (0.99e1.71) <0.001 0.929 <0.001 <0.001 0.419
SOCS3 0.77 (0.58e0.95) 0.89 (0.63e1.14) 0.63 (0.32e0.94) 0.48 (0.14e0.83) 0.035 0.853 0.103 0.018 0.195
All the data are presented as Mean Expression Level (95% CI). Results are expressed relative to levels of HPRT1 mRNA. N: Number of patients.
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0.206e0.923, P ¼ 0.857) (Fig. 2). The difference in DC-STAMP
expression between C-TKA and TKA (P ¼ 0.155) and between C-
THA and THA (P ¼ 0.509) did not reach signiﬁcance. The number of
NF-kB transcripts was higher in tissues from C-TKA (1.109,
0.895e1.322) than in C-THA (0.631, 0.496e0.767, P¼ 0.001) (Fig. 2).
Similarly, elevated expression of NF-kB was observed in TKA (0.825,
0.671e0.979) comparing to THA (0.378, 0.336e0.419, P < 0.0001).
At both joints, patients re-operated for aseptic loosening/osteolysis
had lower NF-kB expression than those with early stages of particle
disease, and no sign of periprosthetic osteolysis/aseptic loosening:
C-TKA vs TKA (P ¼ 0.026) and C-THA vs THA (P ¼ 0.0003).
Immunohistochemistry
In order to assess the protein levels of candidate molecules
recruited from mRNA proﬁling, immunohistochemical staining for
CCL3, DC-STAMP, RANKL, OPG, IL-8 and SOCS3 was performed on
tissue slides from TKA and THA patients and patients undergoing
surgery for primary knee and hip OA.
We detected strong positive staining for CCL3 in tissues in
contact with aseptically failed TKA and THA; a lower protein level
was detected in TKA comparing to THA tissue (Fig. 3). Similarly, DC-
STAMP protein levels were lower in TKA comparing to THA patients
(Fig. 3). In addition, slightly lower IL-8, OPG, and SOCS3 and
increased RANKL protein levels were detected in TKA comparing to
THA (Fig. 3).
When comparing TKA to knee osteoarthritic tissues, higher
CCL3, DC-STAMP, IL-8, and SOCS3 protein levels were detected in
TKA (Fig. 3). On the other hand, lower OPG and RANKL levels were
found in TKA comparing to knee OA (Fig. 3). Similar protein pattern
was observed in failed THA comparing to hip OA (Fig. 3).
Overall, mainly macrophages and multinucleated giant cells
produced the studied proteins in pseudosynovial membranes
retrieved either from patients with aseptically failed TKA or THA.
The contribution of lymphocytes and ﬁbroblasts seemed to be less
frequent. Comparing to osteoarthritic tissues, TKA and THA showed
more inﬁltration of macrophages and giant cells (Fig. 3). Impor-
tantly, in TKA, we observed large giant cells typical by high number
of nuclei [Fig. 4(A), (C)], whereas in THA, smaller giant cells with
only few nuclei were observed [Fig. 4(B), (D)]. The staining with an
osteoclast marker TRAP conﬁrmed that giant cells in failed TKA and
THA are formed predominantly by osteoclast-like cells [Fig. 4(E),
(F)].
In line with the observation in gene EP, the protein levels of
CCL3, DC-STAMP, RANKL, OPG, IL-8, and SOCS3 showed high sim-
ilarities between knee and hip OA. In tissues from osteoarthriticpatients, the studied proteins have been localized mainly to ﬁbro-
blasts and endothelial cells (Fig. 3).
Discussion
Our study revealed that aseptic loosening of TKA is typical by
elevated mRNA expression of IL-8, CHIT1, MMP9, and lower
expression of BMP4, TNF, and OPG comparing to knee OA. When
TKA-proﬁle was compared to THA-proﬁle, lower CCL3 and DC-
STAMP mRNA and protein expression was detected in aseptically
failed TKA. The EP of all studied inﬂammatory and osteoclastogenic
molecules did not differ between groups with knee and hip OA. To
the best of our knowledge, this study represents the most
comprehensive study on gene expression proﬁling in aseptically
failed TKA. Moreover, this is the ﬁrst report on comparison of EP
between aseptically failed TKA and THA, and between knee and hip
OA.
The molecular processes participating in the periprosthetic
osteolysis and aseptic loosening in TKA are not completely under-
stood. We therefore analysed a spectrum of inﬂammatory and
osteoclastogenic molecules in tissues from loosened TKA. In failed
TKA, we found an implication of chemokine IL-8, a cytokine directly
induced in vitro by wear debris9,32 and associated with end-stage of
aseptic loosening in THA17,33,34. Chitinase 1 (CHIT1), an enzyme
contributing to the alternative macrophage activation35 and initi-
ation of bone repair36, was also upregulated in failed TKA
comparing to OA. In accordance with observation in loosened
THA17, we detected also lower levels of BMP4, a stimulator of bone
formation, and upregulation of matrix metalloproteinase MMP9
comparing to OA.
Regarding the pro-inﬂammatory cytokine TNF, we observed
lower expression of TNF in failed TKA than in OA, a disease typical
by overexpression of TNF37. Others17 and we observed the same
pattern also in failed THA in comparison to hip OA. To explain this
ﬁnding, we suggest that these levels might be sufﬁcient to
perpetuate chronic periprosthetic inﬂammatory response. We also
did not observe signiﬁcant difference between IL-6 levels in TKA
and OA. In line with previous study reporting lower levels of IL-6 in
TKA comparing to THA in synovial ﬂuid38, number of IL-6 tran-
scripts in our patients with TKA tended to be lower comparing to
THA. Recent study showed that the absence of IL-6 results in
increased inﬂammatory bone loss39, thus highlighting this cytokine
for further investigation in particle-induced osteolysis. In this
respect, we investigated also SOCS3, an inhibitor of IL-6 signal-
ling40, and observed elevated levels in failed TKA/THA comparing to
OA, reaching signiﬁcance only in THA. SOCS3 has already been
shown induced by wear debris in human osteoclast precursor
Fig. 2. Distribution of relative mRNA expression (ratio target gene/reference HPRT1
gene) of CCL3, DC-STAMP, and NF-kB in pseudosynovial membrane tissues obtained
from patients with (1) aseptically failed TKA and THA (OL/AL) and (2) in patients with
C-TKA and C-THA re-operated for other reasons (pain, instability, fracture), exhibiting
no sign of periprosthetic osteolysis/aseptic loosening at the time of tissue sampling (no
OL/AL). Group means are indicated by horizontal bars, error bars indicate 95% CI; only
P-values for signiﬁcant differences between two groups of patients are stated.
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sponses41. These ﬁndings nominate IL-6/SOCS3 axis for further
research.
Next, we analysed expression of key regulators of bone meta-
bolism RANKL and OPG. In line with previous report in THA17, wedetected no difference in RANKL and lower OPG mRNA expression
in failed TKA comparing to OA. Low expression of RANKL and OPG
in aseptically loosened TKA/THA was conﬁrmed by immunohisto-
chemistry and low concentration of RANKL has been also detected
in pseudosynovial joint ﬂuid42. The RANKL/OPG ratio, shown to be
critical for osteolysis11,43, tended to be higher in failed TKA in
comparison to THA and in TKA/THA comparing to knee/hip OA. In
accordance with others17, we suggest this is rather due to slight
decrease in OPG levels than changes on the side of RANKL
expression levels.
Although synovial samples from primary OA are considered as a
gold standard for tissue studies investigating aseptic loosening and
periprosthetic osteolysis2, we believe that corresponding tissues
retrieved from aseptically failed joint arthroplasty of other
anatomical location could also serve as a useful material. This ﬁrst
study comparing the EP associated with aseptic loosening in TKA
and THA revealed that CCL3 and DC-STAMP were differentially
expressed at mRNA level between both joints. Lower mRNA
expression of CCL3 and DC-STAMP in failed TKA than in THA was
conﬁrmed by immunohistochemistry at the protein level. Previous
studies showed that wear particles in vitro induce expression of
CCL344,45, a chemokine with the most signiﬁcantly decreased
expression in TKA in our study. In implant-associated infection,
CCL3 has been shown to attract predominantly CD8þ T cells, thus
initiating the inﬂammatory response46. It contributes also to
increased migration of human monocytes from peripheral blood to
the site of foreign body response and to cellular tissue migra-
tion13,47. Recent in vitro study showed that CCL3 acts not only as
chemoattractant, but is also able to induce formation of giant cells
with multiple nuclei from monocytes48. Osteoclast differentiation
induced by CCL3 was associated with synthesis of nuclear factor of
activated T cells c1 (NFATc1), a crucial transcription factor for DC-
STAMP and other genes involved in osteoclast fusion48. Another
study showed that CCL3 together with CCL2, 5, 9 are expressed by
foreign body giant cells and are involved in the interaction of
foreign body giant cells with osteoclasts49. DC-STAMP, a next
molecule with lower expression in loosened TKA, has been shown
crucial for cellecell fusion during the differentiation of osteoclasts
and in the development of multinucleated giant cells50. Impor-
tantly, other functions of DC-STAMP are related to regulation of
cytokine production51 and based on its structural similarity with
chemokine receptors also to cellular migration52.
To attain deeper knowledge regarding the potential role of CCL3
and DC-STAMP in the aseptic loosening, we analysed also peri-
prosthetic tissues obtained from patients re-operated for other
aseptic reasons than osteolysis/aseptic loosening (pain of unknown
origin, instability, periprosthetic fracture), with early stages of
particle disease well before osteolysis/aseptic loosening is apparent
on radiographs and/or clinically. We believe that these tissues bear
important information about early (“pre-osteolytic”) stages of
particle disease. Considering our results, we hypothesize that wear
particles released from TKA and THA in patients with “pre-osteo-
lytic” stages (C-TKA, C-THA) induce locally similar levels of CCL3, a
downstream target of NF-kB30, thus implicating this chemokine in
the initiation of inﬂammation at both joints. However, very high
levels of NF-kB in C-TKA comparing to C-THA point to more pro-
nounced inﬂammatory response in TKA than in THA, probably
involving a spectrum of NF-kB downstream targets such as TNF, IL-
6, CCL2/MCP1 and others30. Moreover, elevated NF-kB and its target
genes including DC-STAMP and other known cellecell fusion
molecules53 may enhance osteoclast differentiation and formation
of large highly nucleated osteoclast-like giant cells in TKA.
Conversely, lower NF-kB and its target genes in THAmay contribute
to the formation of smaller osteoclast-like giant cells with only
several nuclei. We speculate that by reaching the steady state in
Fig. 3. Immunohistochemical staining for CCL3, DC-STAMP, IL-8, SOCS3, OPG, RANKL in pseudosynovial membrane sections obtained from patients with aseptically failed TKA and
THA and in synovial membrane sections from patients with primary knee (OA-knee) and hip (OA-hip) OA e representative examples. Typical ﬁbroblasts (solid arrow), endothelial
cells (dashed arrow), lymphocytes (dotted arrow), multinucleated giant cells (empty arrow) are marked. Stainings with a non-speciﬁc isotype control antibody are shown in right
upper segment of each panel. Scale bar, 50 mm.
T. Tomankova et al. / Osteoarthritis and Cartilage 22 (2014) 1851e1860 1857highly nucleated giant cells around TKA prosthesis during “pre-
osteolytic” stages of particle disease (C-TKA), the CCL3 expression
decreases. The decrease of CCL3 may contribute to downregulation
of NFATc148, which at least in part may explain the decreasedexpression of DC-STAMP in TKA. In THA, however, increased CCL3
might contribute to bone resorption at later stages of periprosthetic
osteolysis via its ability to upregulate NFATc1, a known transcrip-
tion factor for DC-STAMP and other genes involved in osteoclast
Fig. 4. H&E and immunohistochemical staining of pseudosynovial membrane sections
obtained from patients with aseptically failed TKA and THA e representative examples.
H&E: Pseudosynovial membrane from aseptically loosened TKA is characterized by
presence of large highly nucleated giant cells (A, C); in THA, smaller giant cells with
less nuclei are present (B, D). The giant cells in both TKA and THA are formed by
osteoclast-like cells as shown by TRAP staining (E, F). Scale bar: A, B 100 mm; C, D, E, F
50 mm.
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less important role in the later stages of aseptic loosening and
osteolysis in THA comparing to TKA and also comparing to pre-
osteolytic stages.
Our study highlights the differences between particle disease in
knee and hip joints as well as the differences between various
stages of osteolysis in both joints. This may be due to different size/
shape/number of polyethylene particles released from TKA in
contrast to THA54. Our results further reinforce a key role of initi-
ating events in particle disease determining the later events leading
to osteolysis, thus indicating the necessity for more comprehensive
investigation of gene expression pattern in various stages of
osteolysis/aseptic loosening at both joints. We are aware that also
other factors of mechanical origin can contribute signiﬁcantly to
aseptic loosening and osteolysis4,55. In line with current knowl-
edge30, our study nominates NF-kB and CCL3 as possible regulators
of processes leading to the development of osteolysis and thus
suggests them as potential therapeutic or prophylactic targets for
patients with TKA and THA.
Since our study revealed differences in EP between aseptically
failed TKA and THA, we aimed also to investigate whether OA of
knee and hip differs in gene and protein expression of studied
molecules. Interestingly, we observed similar proﬁle of investigated
inﬂammatory and osteoclastogenic molecules in OA, irrespective of
the affected joint. In conjunctionwith a recent emphasis on the role
of synovium in the pathogenesis of OA56, our ﬁndings support the
hypothesis on similar mechanisms contributing to the develop-
ment of osteoarthritic synovium in knee and hip joints.
Our study has several limitations, including retrospective data
collection on the preoperative status and index surgery in enrolledpatients, and relatively small number of aseptically failed TKAs.
Moreover, number of patient-, surgery-, implant-related variables
can potentially inﬂuence the stability of TKA and THA making
tremendously difﬁcult interpretation of failure in an individual case.
There is also evidence on potential involvement of other molecules/
pathways in aseptic loosening of knee/hip implant. As example we
mention recent evidence on involvement of IL-17 and Th17 cells in
aseptic loosening57,58 and in stimulation of osteoclastogenesis59.
Although our preliminary gene expression data showed low
expression of IL-17A in the majority of our samples, we observed
upregulation of TGFB1, a critical driver for Th17 pathway, in THA vs
TKA (unpublished results); this ﬁnding deserves further research.
Moreover, to obtain complete picture of the processes ongoing in
aseptic loosening and periprosthetic osteolysis, this study on
pseudosynovial membrane should continue by analysing the
synovial-like interface granulomatous membrane located between
the implant and the bone. We are also aware that investigation of
different stages of osteolysis and other molecules/pathways is
required to better understand the mechanisms underlying osteol-
ysis. However, we believe that detailed characterization of end-
stage of osteolysis may contribute to complex knowledge of the
mechanisms leading to aseptic loosening and osteolysis and also to
nominate candidates for the studies of early stages.
In conclusion, we revealed a difference in expression of CCL3
and DC-STAMP between aseptically failed TKA and THA. In addi-
tion, we found similar EP of a studied set of inﬂammatory and
osteoclastogenic molecules in synovial tissues from knee and hip
OA. Further studies on aseptic loosening mechanisms in TKA and
THA as well as on cytokine signalling network in the local envi-
ronment around total joint arthroplasty, especially in different
stages of osteolysis, are required because only such research may
lead to the proposal of effective preventative and therapeutic
strategies contributing to decreased rate of aseptic failure of TKA
and THA in the future.
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